 |
 |

Treatment of McArdle Disease
Arch Neurol. 2000;57:923-924.
 |
 |
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
 |
 |
WE ARE approaching the 50th anniversary of the classical description by Brian McArdle1 of the metabolic myopathy that bears his name. It was recognized 40 years ago that the symptoms of McArdle diseaseexertional muscle fatigue, pain, cramps (contractures), and myoglobinuriawere due to deficiency of the muscle form of glycogen phosphorylase, and thus were related specifically to the unavailability of muscle glycogen as a source of energy for muscle contraction.2-3 In the last few years, understanding of the molecular pathogenesis of McArdle disease has advanced with the description of approximately 20 different mutations in the phosphorylase gene on chromosome 11.4 However, treatment of McArdle disease has lagged and remains an important clinical challenge.
The opportunity for therapy begins with diagnosis, and diagnosis in McArdle disease rarely is timely. Symptoms of exercise intolerance typically are life long, but the diagnosis is usually not made until the third decade of life, and often . . . [Full Text of this Article]
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
 |
Prevalence of genetic muscle disease in Northern England: in-depth analysis of a muscle clinic population
Norwood et al.
Brain 2009;132:3175-3186.
ABSTRACT
| FULL TEXT
Sweet Success -- A Treatment for McArdle's Disease
Amato
NEJM 2003;349:2481-2482.
FULL TEXT
|